Considering a switch from IVIg to SCIg for primary immunodeficiency? Explore differences in responsibility, side effects, ...

Although the idiotypic structures of immunoglobulin from malignant B cells were the first tumor-specific determinants recognized, and clinical vaccination trials have demonstrated induction of ...

Advances in our understanding of the pathogenesis of rheumatic diseases such as rheumatoid arthritis and systemic lupus erythematosus have led to the emergence of immunoglobulin-based therapy as a ...

Immunoglobulins are large Y-shaped proteins produced by B-cells and plasma cells that are used by the immune system to identify and neutralize foreign objects such as bacteria and viruses.

Findings showed after 52 weeks, significant improvements in 2MWD and 6MWD were seen with Flebogamma 5% DIF 1mg/kg compared with placebo. Topline data were announced from a phase 2/3 trial evaluating ...

In a recent study published in Science Immunology, researchers evaluated immunoglobulin G (IgG) responses to coronavirus disease 2019 (COVID-19) messenger ribonucleic acid (mRNA) vaccinations. Study: ...

For the last eight years, Leslie MacGregor from Newton, Massachusetts, has been getting intravenous infusions every month. The treatment is called immunoglobulin, and it bolsters her defective immune ...

BACKGROUND: Current prescribing information recommends that physicians apply a dose ratio of 1.37:1 (1.53:1 prior to January 2015) in the United States (US) when switching patients with primary ...

A Prescription Drug User Fee Act target date of November 28, 2025 has been set for the application. The Food and Drug Administration (FDA) has accepted for Priority Review the Biologics License ...

In patients with inborn errors of immunity who are prone to viral infections, immunoglobulin replacement therapy (IRT) administered via the conventional subcutaneous route showed lower viral infection ...

Dublin, Sept. 05, 2025 (GLOBE NEWSWIRE) -- The "Immunoglobulin Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2025 ...

In March 2023, Selagine announced a research, development, and sublicense agreement with Grifols, the sponsor of the IND and a global leader in plasma-derived medicines, for the development and ...